User:Mr. Ibrahem/Rotigotine
Clinical data | |
---|---|
Trade names | Neupro, Leganto |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607059 |
License data |
|
Pregnancy category |
|
Routes of administration | Transdermal patch |
Drug class | Dopamine agonist[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 37% (transdermal) |
Protein binding | 92% |
Metabolism | Liver (CYP-mediated) |
Elimination half-life | 5–7 hours |
Excretion | Urine (71%), Fecal (23%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C19H25NOS |
Molar mass | 315.48 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rotigotine, sold under the brand name Neupro among others, used to treat Parkinson's disease (PD) and restless legs syndrome (RLS).[1] It comes as a once-daily skin patch.[1]
Common side effects include nausea, sleepiness, increased sweating, anxiety, and swelling.[1] Other side effects may include anaphylaxis, sleep attacks, psychosis, compulsive gambling, and weight gain.[1] There are concerns regarding safety in pregnancy.[2] It is a dopamine agonist of the non-ergoline class.[1]
Rotigotine was approved for medical use in Europe in 2006 and the United States in 2007.[3][1] In the United States it costs about 750 USD per month as of 2021.[4] In the United Kingdom this amount costs the NHS about £130.[5]
References[edit]
- ^ a b c d e f g h i j "Rotigotine Monograph for Professionals". Drugs.com. Archived from the original on 2 May 2021. Retrieved 19 October 2021.
- ^ "Rotigotine (Neupro) Use During Pregnancy". Drugs.com. Archived from the original on 27 October 2020. Retrieved 19 October 2021.
- ^ "Neupro". Archived from the original on 2 March 2020. Retrieved 19 October 2021.
- ^ "Neupro Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 19 October 2021.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 446. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link)